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Background
HIV transmission most commonly occurs at mucosal sur-
faces, and vaccine development and other preventative
strategies should be directed at the transmitted viruses
that are responsible for establishing productive infection.
The simian immunodeficiency virus (SIV) models of HIV
infection use virus stocks for inoculation of monkeys at
defined times. This greatly simplifies the process of iden-
tifying the transmitted or early founder virus populations,
the variants evolving after transmission that establish sys-
temic infection and the role of viral selection during sex-
ual transmission.
Methods
We used the single genome amplification (SGA) method
to amplify a 2.2 kb env sequence from the SIVmac251
stock and plasma of 7 rhesus macaques at the earliest
plasma vRNA+ time point after intravaginal infection with
SIVmac251. Neighbour-joining methods and Highlighter
analysis were used to analyze the relationships between
the env sequence.
Results
Three animals were infected with a single SIV variant, and
4 animals were infected with multiple (5–9) SIV variants.
The maximum diversity among the env sequences within
an individual animal ranged from 0.18 to 1.10%. Impor-
tantly, a specific env variant representing ~20% of the
sampled stock sequences was directly transmitted to three
animals by vaginal inoculation, perhaps reflecting its rel-
atively high frequency in the stock.
Conclusion
These results are consistent with the low number of HIV
variants transmitted by mucosal HIV exposure. For a vac-
cine or microbicide to be effective, it must interdict the
broadest range of HIV variants possible, including every
clade in the pandemic. However, in any one subject the
number of viruses that must be blocked at each mucosal
exposure event is small, since most viruses in the inocu-
lum are unsuccessful at establishing infection and only
one or few variants establish productive infection.
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